Home
Charts
Search
Watchlist
Products
All IPOs
₹807 - 807
Molbio Diagnostics Ltd
HealthcareIPO
₹807 - 807
We are an innovative point-of-care diagnostics company focused on expanding access to accurate, rapid and costeffective healthcare technologies to diagnose infectious and non-communicable diseases. Our portable and battery operated `Truenat' platform facilitates diagnosis using our disease-specific `Truenat' test kits within an hour and enables screening and diagnosis for 30 diseases, including tuberculosis, COVID, Hepatitis B and C, Human immunodeficiency virus, and Human Papillomavirus, as of March 31, 2025. We also offer devices, enabling radiology, digital pathology and breast health screening. We offer our products globally to public health programs, diagnostic laboratories, and private and public hospitals.
Lot18Min Invest₹14,526Face Value₹1Issue Size₹940 CrFresh Issue₹200 CrOffer for Sale₹740 CrListing Price₹980CMP₹1,161
Timeline
10 Aug
Bidding opens
12 Aug
Bidding closes
13 Aug
Allotment
14 Aug
Refund & demat credit
17 Aug
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹940 Cr1.16 Cr shares
Fresh Issue₹200 Cr
Offer for Sale₹740 Cr
Face Value₹1
Lot Size18 shares
ReservationQIB 50% · NII 15% · RETAIL 35%
Application Sizes
Retail₹14,5261-13 lots
sNII₹2,03,364from 14 lots
bNII₹10,02,294from 69 lots
Managers & Registrar
Lead ManagerKotak Mahindra Capital Company Limited
Co-ManagerIIFL Capital Services Limited, Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited
RegistrarKFin Techologies Ltd
Ownership & Proceeds
Offer for Sale
Selling ShareholderShares OfferedAmt ₹ CrExxora Trading LLPPRMTR18,11,000146.15Dr. Chandrasekhar Bhaskaran NairPRMTR12,21,00098.53Abdul Qadir Mohamed TheruvathOTH48,0003.87Chewbacca Services LimitedOTH1,93,00015.58J. Guru DuttOTH9,02,00072.79Gopalkrishna Mangalore KiniOTH11,25,00090.79Gopalakrishna SampathgiriOTH9,02,00072.79India Business Excellence Fund IIIOTH10,00,00080.70M Ganesh KamathOTH17,0001.37M.A. RohitOTH2,48,00020.01M.A. SharathOTH2,02,00016.30M.A. Usha RaniOTH4,51,00036.40Sangeetha M KiniOTH4,52,00036.48Shaheeda Abdul KaderOTH97,0007.83Shruthi G KiniOTH2,26,00018.24Sujay LimitedOTH1,93,00015.58Vivek DevarajOTH78,0006.29Total91,66,000739.70
Shareholding
CategoryPre IPOPost IPOPromoter Group44.89%41.29%Public55.11%58.71%
Objects of the Issue
- Funding capital expenditure towards the setting up of infrastructure for the company research and development facility, Center of Excellence and connected office space
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for unit 1 & 2
- General corporate purposes
Anchor Book
Bid Date07-Aug-2026
Financials
Profit & Loss
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| RevenueCr | 776 | 332 | 837 | 1,020 | 1,446 |
| Operating ProfitCr | 371 | 43 | 234 | 262 | 321 |
| OPM% | 47.8 | 13.0 | 28.0 | 25.7 | 22.2 |
| PBTCr | 296 | 10 | 130 | 194 | 231 |
| PATCr | 215 | -3 | 84 | 139 | 164 |
| EPS | 974 | 0 | 9 | 13 | 15 |
Balance Sheet
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity CapitalCr | 2 | 2 | 2 | 2 | 11 |
| ReservesCr | 708 | 719 | 821 | 966 | 1,158 |
| BorrowingsCr | 109 | 119 | 184 | 147 | 450 |
| Total AssetsCr | 940 | 1,034 | 1,221 | 1,462 | 2,148 |
Cash Flow
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Operating Cash FlowCr | 101 | 64 | 10 | 287 | 50 |
| Investing Cash FlowCr | -88 | -40 | -45 | -123 | -93 |
| Financing Cash FlowCr | -22 | 18 | -32 | -26 | 276 |
| Net Cash FlowCr | -9 | 43 | -67 | 138 | 233 |
Strengths & Risks
Strengths · as stated in the DRHP
- We are well placed to address unmet demand in a large and growing molecular diagnostic market with gaining credence of point-of-care testing.
- Innovative, R&D focussed business.
- We have developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform.
- We have a scalable business model with strong entry barriers, high proportion of recurring revenues and a growing suite of tests.
- Our strategic collaborations and acquisitions enhance our capabilities and offerings.
- We have a management team with deep domain expertise and track record of delivering strong financial performance.
Strategies · as stated in the DRHP
- Expand our geographical presence in India and across the globe.
- Continue to expand our suite of diagnostic solutions for multiple diseases.
- Develop new POC platforms for other communicable and non-communicable diseases.
- Grow through strategic acquisitions and alliances and establish a centre of excellence.
Risks · as stated in the DRHP
- The company derives a portion of its revenues from the sale of the company's products to the Indian central and state governments, and international aid agencies for their public healthcare programs. The company's revenue from such government and international aid agencies was 84.56%, 87.83% and 91.60% of its revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. Any unfavourable policy changes by these agencies or a decrease in funding for public healthcare programs may impact the sale of the company's products and adversely affect its business, financial condition, results of operations and cash flows. Further, the company's revenue from the top 10 customers was 83.26%, 83.62% and 78.54% of its revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. The loss of any of these customers or a decline in demand for the company's products from them could also have an adverse effect on its business, financial condition, results of operations and cash flows.
- The company derives a portion of its revenues from the sale of diagnostic test kits for tuberculosis ("TB"). Its revenue from the sale of test kits for TB was 70.20%, 69.11% and 62.40% of the company's revenue from contracts with customers - sale of products - finished goods in the Fiscals 2026, 2025 and 2024, respectively. Any decline in the demand for such test kits may have an adverse effect on the company's business, financial condition, results of operation and cash flows.
- The company has invested and intend to continue to invest in research and development ("R&D") efforts to grow its menu of tests. The company cannot assure you that its R&D efforts will result in the successful development and obtaining of government approvals for new tests, which could adversely affect its business, results of operations, and cash flows.
- The company's Subsidiaries, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited and OptraScan INC, have incurred losses in the past and may incur losses in the future which could have an adverse effect on its business, financial condition, results of operations and cash flows. Further, the Company (on a consolidated basis) and some of its Subsidiaries have experienced negative cash flows from operating activities in the past. Any such negative cash flows in the future could affect the company's business, results of operations, financial condition and cash flows.
- The company's Promoters (certain of whom are also Directors) hold Equity Shares in the Company and may be interested in the Company's performance in addition to any remuneration and reimbursement of expenses payable to them.
- If the company is unable to patent new processes and protect its proprietary information or other intellectual property, the company's business may be adversely affected.